IFI16 and neoplasm: Loci that were not commonly reported as targets of gains, losses, or allelic imbalances in colorectal cancers included 1q23.2, 2q11.2, 5q35.2, 11q22.3, and 11q24.1 and their associated target genes also included known tumor suppressors/immune killers such as IL18 [42], OPCML/OBCAM [43], or novel colon cancer genes (IFI16, RGS4, DEDD, AFF3, SORL1, and PDLIM7).